Norway· NO-ID_69D3876B-4374-4497-A914-3A826FFD9EF4
Padcev
A enfortumab vedotin product containing enfortumab vedotin, registered in Norway by Astellas Pharma Europe B.V. - Leiden. The same ATC class is registered in 13 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Enfortumab vedotin is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FX13 (enfortumab vedotin), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 8 of them publish a price we can compare per daily dose
Enfortumab vedotin · ATC L01FX13
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Enfortumab Vedotin
- Manufacturer
- Astellas Pharma Europe B.V. - Leiden
- Country
- Norway (NO)
- ATC code
- L01FX13
- ATC class
- Enfortumab vedotin
- Defined daily dose
- 9.4 mg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_69D3876B-4374-4497-A914-3A826FFD9EF4
- no_varenummer18847030NOK 12653.5
- gtin5703483060022
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
190 interactions on record for enfortumab vedotin.
Graded by severity as the source publishes them — 37 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Enfortumab vedotin · interactions on record
190 records
- 37 severe
- 150 moderate
- 3 minor
Most severe, free to view
- KetoconazoleH02CA03severe
- ClarithromycinJ01FA09severe
- KetoconazoleJ02AB02severe
- Darunavir and cobicistatJ05AR14severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Enfortumab vedotin in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandPadcevAstellas Pharma Europe B.V.
- SpainPADCEV 30 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONAstellas Pharma Europe B.V.
- CzechiaPADCEVAstellas Pharma Europe B.V., Leiden
- United KingdomPadcev 30mg powder for concentrate for solution for infusion vialsAstellas Pharma Ltd
- IrelandPadcev 30 mg Powder for concentrate for solution for infusionAstellas Pharma Europe B.V.
- IcelandPadcevAstellas Pharma Europe B.V.
- PolandPadcevAstellas Pharma Europe B.V.
- BelgiumPadcev 30 mgAstellas Pharma Europe
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Padcev
- Liechtenstein · Padcev
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c67c6cff-e1cb-4dbf-9148-555e33df348a GET /v1/drugs/c67c6cff-e1cb-4dbf-9148-555e33df348a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Pulver til konsentrat til infusjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Enfortumabvedotin",
"merkevare_id": "ID_69D3876B-4374-4497-A914-3A826FFD9EF4",
"name_form_strength": "Padcev pulv til kons til inf væske, oppl 30 mg",
"prescription_group": "C"
}See everything about enfortumab vedotin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.